These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1709563)

  • 1. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
    Larder BA; Kellam P; Kemp SD
    AIDS; 1991 Feb; 5(2):137-44. PubMed ID: 1709563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA; Kemp SD
    Science; 1989 Dec; 246(4934):1155-8. PubMed ID: 2479983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.
    Larder BA; Coates KE; Kemp SD
    J Virol; 1991 Oct; 65(10):5232-6. PubMed ID: 1716689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
    Sheehy N; Desselberger U
    J Gen Virol; 1993 Feb; 74 ( Pt 2)():223-8. PubMed ID: 7679140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
    J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
    Kellam P; Boucher CA; Larder BA
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1934-8. PubMed ID: 1371886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
    Boucher CA; O'Sullivan E; Mulder JW; Ramautarsing C; Kellam P; Darby G; Lange JM; Goudsmit J; Larder BA
    J Infect Dis; 1992 Jan; 165(1):105-10. PubMed ID: 1370174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Larder BA; Darby G; Richman DD
    Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.
    Wildemann B; Haas J; Ehrhart K; Wagner H; Lynen N; Storch-Hagenlocher B
    Neurology; 1993 Dec; 43(12):2659-63. PubMed ID: 7504798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
    Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
    J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1993 Feb; 167(2):445-8. PubMed ID: 7678429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
    Mohri H; Singh MK; Ching WT; Ho DD
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):25-9. PubMed ID: 7678340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method.
    López-Galíndez C; Rojas JM; Nájera R; Richman DD; Perucho M
    Proc Natl Acad Sci U S A; 1991 May; 88(10):4280-4. PubMed ID: 2034672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
    Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
    Richman DD; Grimes JM; Lagakos SW
    J Acquir Immune Defic Syndr (1988); 1990; 3(8):743-6. PubMed ID: 2114476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.